{"commentary":{"count":17,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"podcast":6,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06060613\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"Agni-01","nct_id":"NCT06060613","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=agni-01-nct06060613. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"Agni-01","arms":[{"description":"Participants will receive conditioning therapy prior to administration of OBX-115 regimen.","label":"Participants with advanced solid tumors","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"conditions":["Tumor Skin","Metastatic Melanoma","Melanoma","Lung Cancer","Metastatic Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer"],"enrollment":{"count":254,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"OBX-115","type":"BIOLOGICAL"}],"last_update":"2026-10-05","lead_sponsor":"Obsidian Therapeutics, Inc.","official_title":"A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2029-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence and nature of dose-limiting toxicities (DLTs)","timeFrame":"28 Days"},{"measure":"The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1","timeFrame":"2 years"},{"measure":"The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2023-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06060613"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/agni-01-nct06060613"}